Skip to main content
SpringerLink
Log in

Maternal antimullerian hormone levels do not predict fetal aneuploidy

  • genetics
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To determine if diminished ovarian reserve (measured by maternal antimullerian hormone (AMH) levels), is associated with fetal aneuploidy (determined by prenatal karyotype).

Methods

This case-control study included 213 women with singleton pregnancies who underwent both serum aneuploidy screening and invasive prenatal diagnosis. 18 patients carrying an aneuploid fetus served as cases and the remaining 195 women with a euploid fetus were controls. Serum AMH was measured using two assays: AMHbc (Beckman-Coulter) and AMHdsl (Diagnostic Systems Laboratories). Karyotypes were determined by chorionic villus sampling or amniocentesis.

Results

AMHbc levels did not differ between women with an aneuploid fetus and women with a euploid fetus (p = 0.46) and did not predict aneuploidy (ROC Area = 0.57). Additionally, AMHbc values declined significantly with advancing gestational age.

Conclusions

Maternal AMH does not appear to be a marker of fetal aneuploidy in ongoing pregnancies. Contrary to previous reports, we found a significant decline in maternal AMH levels with advancing gestational age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve—should we perform tests of ovarian reserve routinely? Hum Reprod. 2006;21(11):2729–35.

    Article  PubMed  Google Scholar 

  2. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9.

    Article  CAS  PubMed  Google Scholar 

  3. Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007;88(3):539–46.

    Article  CAS  PubMed  Google Scholar 

  4. Josso N, Picard JY, Rey R, di Clemente N. Testicular anti-Mullerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev. 2006;3(4):347–58.

    PubMed  Google Scholar 

  5. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2008 Nov 29.

  6. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91(10):4057–63.

    Article  CAS  PubMed  Google Scholar 

  7. Fanchin R, Schonauer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod. 2003;18(2):328–32.

    Article  CAS  PubMed  Google Scholar 

  8. La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005;20(6):1569–72.

    Article  PubMed  Google Scholar 

  9. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007;134(2):196–201.

    Article  CAS  PubMed  Google Scholar 

  10. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–62.

    Article  PubMed  Google Scholar 

  11. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83(4):979–87.

    Article  PubMed  CAS  Google Scholar 

  12. Mattei JF, Mattei MG, Ayme S, Giraud F. Origin of the extra chromosome in trisomy 21. Hum Genet. 1979;46(1):107–10.

    Article  CAS  PubMed  Google Scholar 

  13. Boue J, Bou A, Lazar P. Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions. Teratology. 1975;12(1):11–26.

    Article  CAS  PubMed  Google Scholar 

  14. Thum MY, Abdalla HI, Taylor D. Relationship between women’s age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment. Fertil Steril. 2007 Oct 20.

  15. Angell R. First-meiotic-division nondisjunction in human oocytes. Am J Hum Genet. 1997;61(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  16. Angell R. Mechanism of chromosome nondisjunction in human oocytes. Prog Clin Biol Res. 1995;393:13–26.

    CAS  PubMed  Google Scholar 

  17. Pellestor F, Andreo B, Arnal F, Humeau C, Demaille J. Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes. Hum Genet. 2003;112(2):195–203.

    PubMed  Google Scholar 

  18. Kuliev A, Cieslak J, Ilkevitch Y, Verlinsky Y. Chromosomal abnormalities in a series of 6, 733 human oocytes in preimplantation diagnosis for age-related aneuploidies. Reprod Biomed Online. 2003;6(1):54–9.

    Article  PubMed  Google Scholar 

  19. Tsuji K, Nakano R. Chromosome studies of embryos from induced abortions in pregnant women age 35 and over. Obstet Gynecol. 1978;52(5):542–4.

    CAS  PubMed  Google Scholar 

  20. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.

    Google Scholar 

  21. Hassold T, Chiu D. Maternal age-specific rates of numerical chromosome abnormalities with special reference to trisomy. Hum Genet. 1985;70(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  22. Menken J, Trussell J, Larsen U. Age and infertility. Science. 1986;233(4771):1389–94.

    Article  CAS  PubMed  Google Scholar 

  23. Nasseri A, Mukherjee T, Grifo JA, Noyes N, Krey L, Copperman AB. Elevated day 3 serum follicle stimulating hormone and/or estradiol may predict fetal aneuploidy. Fertil Steril. 1999;71(4):715–8.

    Article  CAS  PubMed  Google Scholar 

  24. van Montfrans JM, Dorland M, Oosterhuis GJ, van Vugt JM, Rekers-Mombarg LT, Lambalk CB. Increased concentrations of follicle-stimulating hormone in mothers of children with Down’s syndrome. Lancet. 1999;353(9167):1853–4.

    Article  PubMed  Google Scholar 

  25. Freeman SB, Yang Q, Allran K, Taft LF, Sherman SL. Women with a reduced ovarian complement may have an increased risk for a child with Down syndrome. Am J Hum Genet. 2000;66(5):1680–3.

    Article  CAS  PubMed  Google Scholar 

  26. van Montfrans JM, van Hooff MH, Martens F, Lambalk CB. Basal FSH, estradiol and inhibin B concentrations in women with a previous Down’s syndrome affected pregnancy. Hum Reprod. 2002;17(1):44–7.

    Article  PubMed  Google Scholar 

  27. Kline J, Kinney A, Reuss ML, Kelly A, Levin B, Ferin M, et al. Trisomic pregnancy and the oocyte pool. Hum Reprod. 2004;19(7):1633–43.

    Article  CAS  PubMed  Google Scholar 

  28. Massie JA, Burney RO, Milki AA, Westphal LM, Lathi RB. Basal follicle-stimulating hormone as a predictor of fetal aneuploidy. Fertil Steril. 2008;90(6):2351–5.

    Article  PubMed  Google Scholar 

  29. Weghofer A, Barad D, Li J, Gleicher N. Aneuploidy rates in embryos from women with prematurely declining ovarian function: a pilot study. Fertil Steril. 2007;88(1):90–4.

    Article  PubMed  Google Scholar 

  30. van Montfrans JM, Lambalk CB, van Hooff MH, van Vugt JM. Are elevated FSH concentrations in the pre-conceptional period a risk factor for Down’s syndrome pregnancies? Hum Reprod. 2001;16(6):1270–3.

    Article  PubMed  Google Scholar 

  31. Seifer DB, MacLaughlin DT, Cuckle HS. Serum mullerian-inhibiting substance in Down’s syndrome pregnancies. Hum Reprod. 2007;22(4):1017–20.

    Article  CAS  PubMed  Google Scholar 

  32. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatment. Hum Reprod. 2005;20(4):915–22.

    Article  CAS  PubMed  Google Scholar 

  33. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20(11):3178–83.

    Article  CAS  PubMed  Google Scholar 

  34. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21(8):2022–6.

    Article  CAS  PubMed  Google Scholar 

  35. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, et al. Anti-Mullerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online. 2008;16(5):664–70.

    Article  CAS  PubMed  Google Scholar 

  36. Lutterodt M, Byskov AG, Skouby SO, Tabor A, Yding Andersen C. Anti-Mullerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online. 2009;18(5):694–9.

    Article  PubMed  Google Scholar 

  37. Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of antimullerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2009 Sep 30.

  38. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss 3rd JF. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87(1):101–6.

    Article  CAS  PubMed  Google Scholar 

  39. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007;375(1–2):162–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Beckman Coulter for donating the Immunotech AMH assay kits used for this project.

Funding

1. University of North Carolina Medical Alumni Endowment Fund Grant

2. University of North Carolina Women’s Reproductive HealthResearch (WRHR) Program, 5K12HD050113 (NICHD)

Conflicts of interest

None

Author information

Author notes

  1. Beth J. Plante

    Present address: Warren Alpert Medical School of Brown University, Women and Infants Hospital, Department of Obstetrics and Gynecology, 101 Dudley Street, Providence, RI, 02905, USA

  2. Julie S. Moldenhauer

    Present address: The Children’s Hospital of Philadelphia, The Center for Fetal Diagnosis and Treatment, Philadelphia, PA, 19104, USA

Authors and Affiliations

  1. The University of North Carolina School of Medicine, Department of Obstetrics and Gynecology, CB 7570, Old Clinic Building, Chapel Hill, NC, 27599-7570, USA

    Beth J. Plante, Carmen Beamon, Colleen L. Schmitt, Julie S. Moldenhauer & Anne Z. Steiner

Authors
  1. Beth J. Plante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Beamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Colleen L. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julie S. Moldenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Z. Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beth J. Plante.

Additional information

IRB approval: Protocol approved by the Institutional Review Board at the University of North Carolina at Chapel Hill

Capsule

Maternal antimullerian hormone is not a marker of fetal aneuploidy. Contrary to previous reports, antimullerian hormone levels in pregnancy decline significantly with advancing gestational age.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plante, B.J., Beamon, C., Schmitt, C.L. et al. Maternal antimullerian hormone levels do not predict fetal aneuploidy. J Assist Reprod Genet 27, 409–414 (2010). https://doi.org/10.1007/s10815-010-9433-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-010-9433-4

Keywords

Search

Navigation